![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
The proceeds will be used to complete clinical trials to support product performance, expand brand awareness and product distribution, including Vendaje Optic (amniotic tissue allograft), a structural tissue allograft composed of the amnion layer of the placental membrane.
Lead Product(s): Amniotic Tissue Allograft
Therapeutic Area: Ophthalmology Product Name: Vendaje Optic
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 03, 2023
Details:
Under the agreement, NovaBay has been granted the right to commercialize BioStem Technologies’ Vendaje Optic (amniotic tissue allograft) as Avenova® Allograft, which is intended for use as a protective covering during the repair of ocular surfaces.
Lead Product(s): Amniotic Tissue Allograft
Therapeutic Area: Ophthalmology Product Name: Vendaje Optic
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: NovaBay Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 11, 2023
Details:
VENDAJE is a structural tissue allograft composed of the dehydrated human amniotic membrane of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds.
Lead Product(s): Dehydrated Human Amniotic Membrane
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Vendaje
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
The study investigates a standardized method to quantify the elution of growth factors and cytokines in BioStem’s dehydrated amniotic membrane (Vendaje®) and dehydrated amnion/chorion (Vendaje AC®) placental derived allografts as a function of surface (cm2).
Lead Product(s): Dehydrated Human Amniotic Membrane
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Vendaje
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
The TRIP response indicated that VENDAJE™ does meet the criteria in 21 CFR 1271.10(a) for regulation solely under Section 361 of the Public Health Service Act and 21 CFR 1271.
Lead Product(s): Dehydrated human amniotic membrane allograft
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Vendaje
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2021